Endoscopic Resection for Small Rectal Neuroendocrine Tumors

Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Mar 24, 2025

Keywords

ClinConnect Summary

We aimed to conduct a muticenter randomized controlled trial to compare mEMR-C with mEMR-L for the treatment of small rectal neuroendocrine tumors (NETs) in ten tertiary hospitals in China.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age from 18 to 80 years;
• • 2. With a high suspicion or evidence of rectal NET assessed using EUS or colonoscopy;
• • 3. With tumor size ≤10 mm assessed by colonoscopy;
• • 4. Plan to receive mEMR-C or mEMR-L treatment and provide written informed consent;
• Exclusion Criteria:
• • 1. Unable to tolerate mEMR-L or mEMR-C as assessed by the research team of each center;
• • 2. Complicated with serious diseases such as malignant tumor, which may lead to shorter life expectancy, the research team considers that it is not suitable for inclusion in the study after comprehensive evaluation;
• • 3. Rectal NET with lymph node metastasis or distant metastasis;
• • 4. Received resection of rectal neuroendocrine tumor by other surgical procedures;
• • 5. Multiple rectal neuroendocrine tumors;
• • 6. Vulnerable groups such as pregnant women or patients with mental disorders;
• • 7. Poor compliance, unable to cooperate with treatment.